Literature DB >> 32243786

CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

Dan Wang1, Feng Zhang2, Guangping Gao3.   

Abstract

The development of clustered regularly interspaced short-palindromic repeat (CRISPR)-based biotechnologies has revolutionized the life sciences and introduced new therapeutic modalities with the potential to treat a wide range of diseases. Here, we describe CRISPR-based strategies to improve human health, with an emphasis on the delivery of CRISPR therapeutics directly into the human body using adeno-associated virus (AAV) vectors. We also discuss challenges facing broad deployment of CRISPR-based therapeutics and highlight areas where continued discovery and technological development can further advance these revolutionary new treatments.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32243786      PMCID: PMC7236621          DOI: 10.1016/j.cell.2020.03.023

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  165 in total

1.  Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq.

Authors:  Beeke Wienert; Stacia K Wyman; Christopher D Richardson; Charles D Yeh; Pinar Akcakaya; Michelle J Porritt; Michaela Morlock; Jonathan T Vu; Katelynn R Kazane; Hannah L Watry; Luke M Judge; Bruce R Conklin; Marcello Maresca; Jacob E Corn
Journal:  Science       Date:  2019-04-18       Impact factor: 47.728

2.  Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Authors:  Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru
Journal:  Circ Res       Date:  2014-06-10       Impact factor: 17.367

3.  Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.

Authors:  Morgan L Maeder; Michael Stefanidakis; Christopher J Wilson; Reshica Baral; Luis Alberto Barrera; George S Bounoutas; David Bumcrot; Hoson Chao; Dawn M Ciulla; Jennifer A DaSilva; Abhishek Dass; Vidya Dhanapal; Tim J Fennell; Ari E Friedland; Georgia Giannoukos; Sebastian W Gloskowski; Alexandra Glucksmann; Gregory M Gotta; Hariharan Jayaram; Scott J Haskett; Bei Hopkins; Joy E Horng; Shivangi Joshi; Eugenio Marco; Rina Mepani; Deepak Reyon; Terence Ta; Diana G Tabbaa; Steven J Samuelsson; Shen Shen; Maxwell N Skor; Pam Stetkiewicz; Tongyao Wang; Clifford Yudkoff; Vic E Myer; Charles F Albright; Haiyan Jiang
Journal:  Nat Med       Date:  2019-01-21       Impact factor: 53.440

4.  In vivo base editing of post-mitotic sensory cells.

Authors:  Wei-Hsi Yeh; Hao Chiang; Holly A Rees; Albert S B Edge; David R Liu
Journal:  Nat Commun       Date:  2018-06-05       Impact factor: 14.919

5.  Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6.

Authors:  Rasmus O Bak; Daniel P Dever; Andreas Reinisch; David Cruz Hernandez; Ravindra Majeti; Matthew H Porteus
Journal:  Elife       Date:  2017-09-28       Impact factor: 8.140

6.  Precise therapeutic gene correction by a simple nuclease-induced double-stranded break.

Authors:  Sukanya Iyer; Sneha Suresh; Dongsheng Guo; Katelyn Daman; Jennifer C J Chen; Pengpeng Liu; Marina Zieger; Kevin Luk; Benjamin P Roscoe; Christian Mueller; Oliver D King; Charles P Emerson; Scot A Wolfe
Journal:  Nature       Date:  2019-04-03       Impact factor: 49.962

7.  Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Yaoying Wu; Matthew P Gemberling; Matthew L Oliver; Matthew A Waller; Joel D Bohning; Jacqueline N Robinson-Hamm; Karen Bulaklak; Ruth M Castellanos Rivera; Joel H Collier; Aravind Asokan; Charles A Gersbach
Journal:  Nat Med       Date:  2019-02-18       Impact factor: 53.440

8.  Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing.

Authors:  Nicola Crosetto; Abhishek Mitra; Maria Joao Silva; Magda Bienko; Norbert Dojer; Qi Wang; Elif Karaca; Roberto Chiarle; Magdalena Skrzypczak; Krzysztof Ginalski; Philippe Pasero; Maga Rowicka; Ivan Dikic
Journal:  Nat Methods       Date:  2013-03-17       Impact factor: 28.547

9.  CRISPR RNA-guided activation of endogenous human genes.

Authors:  Morgan L Maeder; Samantha J Linder; Vincent M Cascio; Yanfang Fu; Quan H Ho; J Keith Joung
Journal:  Nat Methods       Date:  2013-07-25       Impact factor: 28.547

10.  Adenine base editing in an adult mouse model of tyrosinaemia.

Authors:  Chun-Qing Song; Tingting Jiang; Michelle Richter; Luke H Rhym; Luke W Koblan; Maria Paz Zafra; Emma M Schatoff; Jordan L Doman; Yueying Cao; Lukas E Dow; Lihua Julie Zhu; Daniel G Anderson; David R Liu; Hao Yin; Wen Xue
Journal:  Nat Biomed Eng       Date:  2019-02-25       Impact factor: 25.671

View more
  90 in total

1.  Multicellular Systems to Translate Somatic Cell Genome Editors to Humans.

Authors:  Victor Hernandez-Gordillo; Thomas Caleb Casolaro; Mo R Ebrahimkhani; Samira Kiani
Journal:  Curr Opin Biomed Eng       Date:  2020-10-10

2.  Getting Back to Normal: Correcting SCN by Universal or Precision Strikes.

Authors:  Hrishikesh M Mehta; Seth J Corey
Journal:  Mol Ther       Date:  2020-11-10       Impact factor: 11.454

Review 3.  Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.

Authors:  Paul Boucher; Xiaoxia Cui; David T Curiel
Journal:  J Control Release       Date:  2020-09-03       Impact factor: 9.776

4.  Gene Editing to the Rescue: Reversal of Social Deficits Associated with MECP2 Duplication.

Authors:  Zi-Xian Yu; Dan-Yang Wang; Xiao-Hong Xu
Journal:  Neurosci Bull       Date:  2020-05-29       Impact factor: 5.203

5.  Detect-seq reveals out-of-protospacer editing and target-strand editing by cytosine base editors.

Authors:  Zhixin Lei; Haowei Meng; Zhicong Lv; Menghao Liu; Huanan Zhao; Hao Wu; Xiaoxue Zhang; Lulu Liu; Yuan Zhuang; Kailin Yin; Yongchang Yan; Chengqi Yi
Journal:  Nat Methods       Date:  2021-06-07       Impact factor: 28.547

6.  Toward the correction of muscular dystrophy by gene editing.

Authors:  Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-30       Impact factor: 11.205

Review 7.  Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa.

Authors:  Da Meng; Sara D Ragi; Stephen H Tsang
Journal:  Mol Ther       Date:  2020-08-25       Impact factor: 11.454

Review 8.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

9.  Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes.

Authors:  Chunlong Xu; Yingsi Zhou; Qingquan Xiao; Bingbing He; Guannan Geng; Zikang Wang; Birong Cao; Xue Dong; Weiya Bai; Yifan Wang; Xiang Wang; Dongming Zhou; Tanglong Yuan; Xiaona Huo; Jinsheng Lai; Hui Yang
Journal:  Nat Methods       Date:  2021-05-03       Impact factor: 28.547

10.  Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.

Authors:  Ye Wu; Weili Jin; Qixue Wang; Junhu Zhou; Yunfei Wang; Yanli Tan; Xiaoteng Cui; Fei Tong; Eryan Yang; Jian Wang; Chunsheng Kang
Journal:  Mol Ther       Date:  2021-07-16       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.